Trinity Biotech (TRIB) Debt to Equity (2016 - 2025)
Historic Debt to Equity for Trinity Biotech (TRIB) over the last 10 years, with Q2 2025 value amounting to -$1.71.
- Trinity Biotech's Debt to Equity rose 2520.5% to -$1.71 in Q2 2025 from the same period last year, while for Jun 2025 it was -$1.71, marking a year-over-year increase of 2520.5%. This contributed to the annual value of -$2.1 for FY2024, which is 2405.04% down from last year.
- Latest data reveals that Trinity Biotech reported Debt to Equity of -$1.71 as of Q2 2025, which was up 2520.5% from -$2.1 recorded in Q4 2024.
- In the past 5 years, Trinity Biotech's Debt to Equity ranged from a high of $6.66 in Q3 2022 and a low of -$20.36 during Q4 2022
- For the 4-year period, Trinity Biotech's Debt to Equity averaged around -$3.77, with its median value being -$2.29 (2024).
- The largest annual percentage gain for Trinity Biotech's Debt to Equity in the last 5 years was 9166.59% (2023), contrasted with its biggest fall of 22026.5% (2023).
- Quarter analysis of 4 years shows Trinity Biotech's Debt to Equity stood at -$20.36 in 2022, then surged by 91.67% to -$1.7 in 2023, then dropped by 24.05% to -$2.1 in 2024, then grew by 18.71% to -$1.71 in 2025.
- Its Debt to Equity stands at -$1.71 for Q2 2025, versus -$2.1 for Q4 2024 and -$2.52 for Q3 2024.